Written question asked by Baroness Ritchie of Downpatrick (Labour) on Wednesday, 21 January 2026, in the House of Lords. It was due for an answer on Wednesday, 4 February 2026. It was answered by Baroness Merron (Labour) on Thursday, 5 February 2026 on behalf of the Department of Health and Social Care.
Vaccination
- Question
-
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 5 January (HL12579), whether they will review the evaluation framework used to inform advice from the Joint Committee on Vaccination and Immunisation to ensure that it systematically captures the wider economic and societal benefits of vaccination, including impacts on productivity, education, and health inequalities.
- Answer
-
When advising the Government on matters relating to vaccination and immunisation, the Joint Committee on Vaccination and Immunisation (JCVI) considers information on cost-effectiveness alongside evidence of the burden of disease, of vaccine safety and efficacy, and of the impact of immunisation strategies. Broader socio-economic impacts of vaccination may be highlighted by the JCVI or by officials who provide advice to ministers. However, these wider impacts are not formally included with the cost-effectiveness methodology.
A key reason for this is that these wider benefits cannot be quantified consistently across all vaccination programmes, due to the lack of high-quality data on socio-economic benefits currently available. Robust data may be available for very few programmes, but basing decisions on these wider benefits, rather than health benefits, would create disparities whereby vaccination programmes with high-quality data on wider benefits are considered more valuable.
Additionally, by maintaining a formal approach focused on health benefits, we are able to assess vaccines consistently with other health interventions in receipt of health spending, which are similarly focused on health benefits under the guidance of the National Institute for Health and Care Excellence (NICE).
By ensuring vaccine policymaking is informed by comparable and measurable health benefits and rigorous cost-effectiveness analysis, we ensure that public funds are spent responsibly and directed to programmes that deliver health benefits and savings to the health and social care system.
Secondary information
- Type
- Written question
- Reference
- HL13800
- Session
- 2024-26
- Related items
- Subjects
- Vaccination
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-03-24 11:46:02 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL13800
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL13800
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL13800